February 3, 2017 /

Mission DMD: FibroGen’s Anti-Fibrosis Program (February 2017)

Parent Project Muscular Dystrophy by: Parent Project Muscular Dystrophy


Mission DMD: FibroGen’s Anti-Fibrosis Program (February 2017)

On February 1, 2017, PPMD and FibroGen hosted a webinar to discuss FibroGen’s investigational drug Pamrevlumab (FG-3019), along with FibroGen’s Mission DMD program that is currently being conducted to investigate Pamrevlumab in Duchenne.

Research & Clinical Trial Webinars, Webinars
Posted on February 3, 2017
LinkedinPin ItWhatsApp

Join Our Mailing List